Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment

Stereotactic irradiation of implanted murine tumors increased proliferation of regulatory T cells (Tregs) within tumors. These cells were functionally more suppressive than Tregs derived from unirradiated tumors, highlighting a potential counterbalance to the immunogenic effects of radiotherapy. Radiotherapy (RT) enhances innate and adaptive antitumor immunity; however, the effects of radiation on suppressive immune cells, such as regulatory T cells (Treg), in the tumor microenvironment (TME) are not fully elucidated. Although previous reports suggest an increased Treg infiltration after radiation, whether these Tregs are functionally suppressive remains undetermined. To test the hypothesis that RT enhances the suppressive function of Treg in the TME, we selectively irradiated implanted tumors using the small animal radiation research platform (SARRP), which models stereotactic radiotherapy in human patients. We then analyzed tumor-infiltrating lymphocytes (TIL) with flow-cytometry and functional assays. Our data showed that RT significantly increased tumor-infiltrating Tregs (TIL-Treg), which had higher expression of CTLA-4, 4-1BB, and Helios compared with Tregs in nonirradiated tumors. This observation held true across several tumor models (B16/F10, RENCA, and MC38). We found that TIL-Tregs from irradiated tumors had equal or improved suppressive capacity compared with nonirradiated tumors. Our data also indicated that after RT, Tregs proliferated more robustly than other T-cell subsets in the TME. In addition, after RT, expansion of Tregs occurred when T-cell migration was inhibited using Fingolimod, suggesting that the increased Treg frequency was likely due to preferential proliferation of intratumoral Treg after radiation. Our data also suggested that Treg expansion after irradiation was independent of TGFβ and IL33 signaling. These data demonstrate that RT increased phenotypically and functionally suppressive Tregs in the TME. Our results suggest that RT might be combined effectively with Treg-targeting agents to maximize antitumor efficacy. Cancer Immunol Res; 5(11); 992–1004. ©2017 AACR.

[1]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[2]  H. Turnquist,et al.  Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. , 2016, Blood.

[3]  R. Fietkau,et al.  Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation , 2016, Front. Oncol..

[4]  C. Melief,et al.  Vaccines for established cancer: overcoming the challenges posed by immune evasion , 2016, Nature Reviews Cancer.

[5]  Deepali V. Sawant,et al.  Interleukin-35 Limits Anti-Tumor Immunity. , 2016, Immunity.

[6]  R. Drapkin,et al.  Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model , 2015, Oncoimmunology.

[7]  S. Demaria,et al.  Role of Local Radiation Therapy in Cancer Immunotherapy. , 2015, JAMA oncology.

[8]  C. Drake,et al.  Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. , 2015, The Lancet. Oncology.

[9]  M. Merad,et al.  CDKN1A regulates Langerhans cell survival and promotes Treg cell generation upon exposure to ionizing irradiation , 2015, Nature Immunology.

[10]  Seoae Cho,et al.  Single high-dose irradiation aggravates eosinophil-mediated fibrosis through IL-33 secreted from impaired vessels in the skin compared to fractionated irradiation. , 2015, Biochemical and biophysical research communications.

[11]  S. Estrem,et al.  Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway , 2015, Drug design, development and therapy.

[12]  H. Baker,et al.  Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 , 2015, The Journal of Immunology.

[13]  J. Zavadil,et al.  TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. , 2015, Cancer research.

[14]  V. Paradis,et al.  Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients , 2015, Oncotarget.

[15]  R. Weichselbaum,et al.  The immunology of ablative radiation. , 2015, Seminars in radiation oncology.

[16]  T. Yen,et al.  TGF-β1 mediates the radiation response of prostate cancer , 2015, Journal of Molecular Medicine.

[17]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[18]  R. Weichselbaum,et al.  STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.

[19]  H. Turnquist,et al.  IL-33 Is an Unconventional Alarmin That Stimulates IL-2 Secretion by Dendritic Cells To Selectively Expand IL-33R/ST2+ Regulatory T Cells , 2014, The Journal of Immunology.

[20]  T. Yen,et al.  TGF-β1 mediates the radiation response of prostate cancer , 2014, Journal of Molecular Medicine.

[21]  P. Newell,et al.  TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models , 2014, Cancer Immunology Research.

[22]  M. Stuschke,et al.  Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells , 2014, Radiation oncology.

[23]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[24]  G. Plitas,et al.  Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy , 2013, The Journal of experimental medicine.

[25]  B. Schilling,et al.  Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer , 2013, Clinical Cancer Research.

[26]  R. Weichselbaum,et al.  Radiation as an immune modulator. , 2013, Seminars in radiation oncology.

[27]  R. Weichselbaum,et al.  New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology , 2013, Science Translational Medicine.

[28]  S. Demaria,et al.  Radiation as an immunological adjuvant: current evidence on dose and fractionation , 2012, Front. Oncol..

[29]  M. Barcellos-Hoff,et al.  Resistance of glioblastoma-initiating cells to radiation mediated by the tumor microenvironment can be abolished by inhibiting transforming growth factor-β. , 2012, Cancer research.

[30]  E. Diamandis,et al.  Abstract 4119: High-throughput proteomics reveals that enzymes of the ketogenic pathway are upregulated during prostate cancer progression , 2012 .

[31]  D. Getnet,et al.  Phenotypic and Functional Properties of Helios+ Regulatory T Cells , 2012, PloS one.

[32]  Jedd D. Wolchok,et al.  Immunologic correlates of the abscopal effect in a patient with melanoma. , 2012, The New England journal of medicine.

[33]  J. DeMarco,et al.  Radiation enhances regulatory T cell representation. , 2011, International journal of radiation oncology, biology, physics.

[34]  K. Isse,et al.  IL-33 Expands Suppressive CD11b+ Gr-1int and Regulatory T Cells, including ST2L+ Foxp3+ Cells, and Mediates Regulatory T Cell-Dependent Promotion of Cardiac Allograft Survival , 2011, The Journal of Immunology.

[35]  David Artis,et al.  Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus , 2011, Nature Immunology.

[36]  U. Beier,et al.  Helios Expression Is a Marker of T Cell Activation and Proliferation , 2011, PloS one.

[37]  N G Burnet,et al.  Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers , 2011, British Journal of Cancer.

[38]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[39]  C. Drake.  Radiation-Induced Immune Modulation , 2011 .

[40]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[41]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[42]  M. Crittenden,et al.  Combination approaches to immunotherapy: the radiotherapy example. , 2009, Immunotherapy.

[43]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[44]  Peter Kazanzides,et al.  High-resolution, small animal radiation research platform with x-ray tomographic guidance capabilities. , 2008, International journal of radiation oncology, biology, physics.

[45]  T. So,et al.  Immune regulation and control of regulatory T cells by OX40 and 4-1BB. , 2008, Cytokine & growth factor reviews.

[46]  Iñaki F Trocóniz,et al.  Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. , 2008, European journal of cancer.

[47]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[48]  A. Rudensky,et al.  Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice , 2007, Nature Immunology.

[49]  K. Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.

[50]  J. Massagué,et al.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. , 2005, Cancer cell.

[51]  R. Proia,et al.  The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. , 2005, Blood.

[52]  Li Li,et al.  Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 , 2003, The Journal of experimental medicine.

[53]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[54]  M. Martin,et al.  TGF-beta1 and radiation fibrosis: a master switch and a specific therapeutic target? , 2000, International journal of radiation oncology, biology, physics.